NCT05749549View on ClinicalTrials.gov

Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Advanced CancerFollicular LymphomaPeripheral T Cell LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

BR1733

Subjects will receive oral administration of BR1733.

Trial Locations (1)

Unknown

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

All Listed Sponsors
lead

Shanghai Blueray Biopharma Co., Ltd.

INDUSTRY